FDA selects Eli Lilly and Regeneron among 7 firms to speed drug manufacturing facility reviews

Key Facts

In a move to strengthen U.S. pharmaceutical supply chain resilience, the Food and Drug Administration has selected Eli Lilly (LLY) and Regeneron (REGN) among seven companies for a pilot program designed to accelerate federal reviews of new domestic drug manufacturing facilities. The program allows selected firms to submit pre-market facility applications, potentially shortening regulatory approval timelines and speeding drug launches.

The selection comes amid growing focus on onshoring drug production to reduce reliance on foreign supply chains. Per market data, LLY traded at $1,206.91 (June 29, 2026), while REGN closed at $632.90 (June 26, 2026). Both companies have extensive pipelines of critical medicines, and faster facility approvals could support production expansion plans and improve long-term operating margins.

Investors will watch whether the program yields faster approvals for new LLY and REGN plants, which could positively impact future revenues. Technically, LLY holds above support near $1,200, while REGN trades below $640. No major sector-specific catalysts are imminent on the calendar, but the announcement reinforces market confidence in a more innovation-friendly regulatory environment.